Research Paper Volume 12, Issue 14 pp 14633—14648

ASNEO: Identification of personalized alternative splicing based neoantigens with RNA-seq

class="figure-viewer-img"

Figure 5. Relationships between neoantigen burden and patient response undergo immunotherapy treatment. For van Allen cohort, the somatic neoantigen burden was significant associated with patient response to immunotherapy treatment (Wilcoxon test, P=0.031, A), while AS neoantigen burden was not associated with response (Wilcoxon test, P=0.93, C). For Hugo cohort, the somatic neoantigen burden was not associated with response (Wilcoxon test, P=0.37, B), while AS neoantigen burden was significant associated with response (Wilcox test, P=0.029, D). Overall neoantigen burden showed no association with response neither in van Allen cohort (Wilcox test, P=0.24, E) nor in Hugo cohort (Wilcox test, P=0.2, F). CB: Clinical Benefit, NCB: No Clinical Benefit.